GlassScriptPhysician profile
Joyce S Shen
NPI 1992017867
$5,791.77
in general payments reported to CMS, 2019-2025
30 companies · $221 in 2025
The $221 reported for 2025 was more than what 78% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $818 · 2021: $1,248 · 2022: $1,398 · 2023: $597 · 2024: $545 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $871.69 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $721.02 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $647.20 | 2019-2025 | |
| Pfizer INC. | $632.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $555.28 | 2019-2025 | Airsupra |
| Electromed, INC. | $302.68 | 2019-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $260.48 | 2019-2023 | Dificid |
| Philips North America LLC | $209.78 | 2022 | |
| Abbvie INC. | $187.16 | 2021-2024 | Teflaro, Dalvance, Avycaz |
| Paratek Pharmaceuticals, INC. | $182.99 | 2020-2023 | Nuzyra |
| Gilead Sciences, INC. | $167.21 | 2021-2024 | |
| Novo Nordisk INC | $123.51 | 2019-2025 | Rybelsus, Ozempic |
| Shionogi INC | $116.64 | 2024 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.73 | 2019-2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $90.57 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $77.67 | 2020-2022 | |
| Abbott Laboratories | $71.63 | 2022 | |
| Allergan, INC. | $71.01 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.10 | 2022-2024 | Lifevest |
| Lundbeck LLC | $56.99 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $53.43 | 2021-2023 | Ultomiris |
| Nabriva Therapeutics, Plc | $42.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $36.64 | 2019 | |
| Masimo Corporation | $35.26 | 2021-2025 | Patient Safetynet System |
| Medtronic, INC. | $18.37 | 2021 | |
| Tactile Systems Technology INC | $18.21 | 2019 | |
| Insmed, INC. | $16.68 | 2023 | Arikayce |
| Amgen INC. | $15.78 | 2019 | |
| Smith+Nephew, INC. | $13.60 | 2020 | |
| Lilly USA, LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.